Remove topic pricing
article thumbnail

GaBI Journal Publishes ASBM Whitepaper on Medicare Part D Price Setting 

Safe Biologics

In January, the Generics and Biosimilars Initiative (GaBI) published a whitepaper entitled “ Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines” The paper’s content is drawn from a webinar on the same topic hosted by ASBM and GaBI on July 26, 2023.

article thumbnail

Opinion: Most-read First Opinion essays of 2022

STAT

The 22nd year of the 21st century, like most years before it, had its share of turbulence, offering opinion/perspective authors a wealth of topics to write about.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

STAT

We cover all these topics and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation.

article thumbnail

Q&A with Kelly Baker, CFO of Eversana

PharmExec

Baker spoke on topics ranging from pricing, access, the war for talent, and other key areas that are impacting pharma companies.

105
105
article thumbnail

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars

Safe Biologics

The most recen t of the webinars, hosted July 29th, examined the negative impact of the Inflation Reducation Act’s Medicare drug price setting provisions. The webinar was the fourth in a series covering key health policy issues.

article thumbnail

Informa Connect’s Life Sciences Pricing & Contracting USA

Drug Channels

Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, Drug Price Transparency, Commercial Contracting or Chargebacks , we have you covered!

article thumbnail

December 2023 Newsletter

Safe Biologics

Participants discussed how the price-setting policy will result in fewer drugs being developed, reduced patient access to these medicines, and will likely fail to control costs as its proponents claim. The paper’s content is drawn from a webinar on the same topic hosted by ASBM and GaBI on July 26, 2023.